TD Cowen lowered the firm’s price target on Standard BioTools (LAB) to $1.35 from $1.55 and keeps a Hold rating on the shares. The firm said there were no surprises in the print with the company now reporting continuing operations revenue post the announced sale of SomaLogic.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Standard BioTools Inc. Reports Q3 2025 Financial Results
- Cautious Hold Rating for Standard BioTools Amid Economic Challenges and Uncertain Strategic Outlook
- Standard BioTools Implements Restructuring for Future Growth
- LAB Upcoming Earnings Report: What to Expect?
- Standard BioTools Announces Workforce Reduction Plan